Trial reportTrials2026
Cipepofol for adjunctive sedation during neuraxial anesthesia: a study protocol for a randomized controlled trial.
Trial report in Trials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCipepofol is a novel 2,6-disubstituted phenol derivative increasingly used for anesthesia and sedation during gastrointestinal endoscopy and fiberoptic bronchoscopy. This study aimed to evaluate the efficacy and safety of cipepofol for adjunctive sedation during neuraxial anesthesia, thereby providing evidence for its clinical application.
methodsThis was a randomized, double-blind, non-inferiority trial. Eligible patients were randomly assigned in a 1:1 ratio to either the cipepofol group or the propofol group using a random number table. The target sedation level was defined as a Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score of 3-4. Patients allocated to the cipepofol group received an intravenous loading dose of 0.1 mg/kg cipepofol administered over 30 ± 10 s, followed by a continuous infusion initiated at 0.3 mg/kg/h to achieve the target sedation level. Those in the propofol group received an intravenous loading dose of 0.5 mg/kg propofol administered over 30 ± 10 s, followed by a continuous infusion initiated at 1.5 mg/kg/h. The primary outcome was the sedation success rate. Secondary outcomes included the following: the percentage of total study drug administration time during which MOAA/S scores were maintained at 3-4, 1-2, or 5, respectively; time from the start of the intravenous loading dose to the first occurrence of MOAA/S score < 4, and the proportion of subjects achieving MOAA/S score < 4 within 3 min; proportion of subjects requiring rescue sedation; the vital signs of subjects; number of dose adjustments and total sedative drug consumption; time from discontinuation of the study drug infusion to the first postoperative MOAA/S score of 5, length of stay in the post-anesthesia care unit (PACU), and recovery status at PACU discharge; satisfaction levels of the anesthesiologist, surgeon, and subjects. DISCUSSION: The purpose of this study is to evaluate the efficacy and safety of cipepofol as an adjunct sedative during neuraxial anesthesia. If cipepofol demonstrates beneficial properties comparable to propofol for adjunctive sedation during neuraxial anesthesia, it could serve as a viable clinical alternative.
trial registrationChinese Clinical Trial Registry ChiCTR2500102635. Registered on 16 May 2025, www.chictr.org.cn . Prospectively registered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.